Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.52 |
| ▸ | DPYD | Q12882 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9654185 | 0.78 | KDM3B (0.50) | GAAATAD2MAPTALDH1A1 | |
| Thymine SCHEMBL5235 | 0.69 | — | — | |
| Thymine SCHEMBL29669526 | 0.69 | — | — | |
| SCHEMBL48366 | 0.69 | — | — | |
| Thymine SCHEMBL17201833 | 0.69 | ATAD2 (1.00) | GAAATAD2DPYDMAPTALDH1A1 | |
| SCHEMBL13071676 | 0.69 | — | — | |
| Thymine SCHEMBL750450 | 0.69 | ATAD2 (1.00) | GAAATAD2DPYDMAPTALDH1A1 | |
| Thymine SCHEMBL3025204 | 0.68 | ATAD2 (0.86) | GAAATAD2DPYDMAPTALDH1A1 | |
| Fluorouracil SCHEMBL27927726 | 0.68 | LMNA (0.86) | GAAATAD2DPYDMAPTALDH1A1 | |
| Thymine SCHEMBL8304490 | 0.68 | ATAD2 (0.86) | GAAATAD2DPYDMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2680822-B1 | VESICLE COMPOSITIONS | SENSULIN LLC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20160280688-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-29 | — | — | US | disclosed |
| CN-102803216-B | Heterocylic antiviral compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-06 | — | — | CN | disclosed |
| CN-102971305-B | Heterocyclic antiviral compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-03 | — | — | CN | disclosed |
| CN-102762574-B | Benzoxapi 3K inhibitor compounds and methods of use | HOFFMAN-LA ROCHE LTD. (CH) | 2015-12-02 | — | — | CN | disclosed |
| WO-2006100119-A1 | DERIVATIVES OF IMIDAZO (1,2-A) PYRIDINE USEFUL AS MEDICAMENTS FOR TREATING GASTROINTESTINAL DISEASES | GLAXO GROUP LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060120958-A1 | Solid-phase fluorination of uracil and cytosine | HAMMERSMITH IMANET LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| CN-1678353-A | Novel anticancer compounds | PSIMEI PHARMACEUTICALS PLC (GB) | 2005-10-05 | — | — | CN | disclosed |
| EP-1572249-A1 | SOLID-PHASE FLUORINATION OF URACIL AND CYTOSINE | Hammersmith Imanet Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| US-20050180917-A1 | Delivery of neutron capture elements for neutron capture therapy | PSIMEI PHARMACEUTICALS PLC (GB) | 2005-08-18 | — | — | US | disclosed |
| EP-1534347-A2 | CONJUGATES OF N-HYDROXYPROPYMETHACRYLAMIDE-METHACRYLATE COPOLYMER WITH NUCLIDE ACTIVATION AGENT AND/OR ANTI-CANCER COMPOUNDS | Psimei Pharmaceuticals Plc (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004056400-A1 | SOLID-PHASE FLUORINATION OF URACIL AND CYTOSINE | HAMMERSMITH IMANET LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004009136-A2 | CONJUGATES OF N-HYDROXYPROPYMETHACRYLAMIDE-METHACRYLATE COPOLYMER WITH NUCLIDE ACTIVATION AGENT AND/OR ANTI-CANCER COMPOUNDS | PSIMEI PHARMACEUTICALS PLC (GB) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009135-A2 | CONJUGATES OF BIOCOMPATIBLE POLYMERS WITH NUCLIDE ACTIVATION THERAPY REAGENTS | PSIMEI PHARMACEUTICALS PLC (GB) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | GAA 180/4885ATAD2 1157/4885DPYD 1475/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | GAA 180/4885ATAD2 1157/4885DPYD 1475/4885 |
| US-20160280688-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | PAH, PEPD, AADAT | GAA 643/4885ATAD2 4134/4885DPYD 329/4885 |
| US-20060120958-A1 | Solid-phase fluorination of uracil and cytosine | SLC29A1, NUDT1, TYMP | GAA 3544/4885ATAD2 3050/4885DPYD 21/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | GAA 180/4885ATAD2 1157/4885DPYD 1475/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | GAA 180/4885ATAD2 1157/4885DPYD 1475/4885 |
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | GAA 967/4885ATAD2 3552/4885DPYD 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.